Charting the future of esophageal cancer translation: insights from clinical trial landscape

被引：0
作者：
Hong, Hujian [1 ,2 ]
He, Yijiang [1 ]
Li, Yan [1 ,3 ]
Shen, Yongyan [1 ,3 ]
Qu, Yanli [1 ]
机构：
[1] Dalian Univ Technol, China Med Univ, Liaoning Canc Hosp & Inst, Dept Radiotherapy,Canc Hosp, Shenyang, Peoples R China
[2] Dalian Med Univ, Grad Sch, Dalian, Peoples R China
[3] China Med Univ, Grad Sch, Shenyang, Peoples R China
来源：
INTERNATIONAL JOURNAL OF SURGERY | 2025年 / 111卷 / 03期
关键词：
CHEMOTHERAPY;
D O I：
10.1097/JS9.0000000000002254
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：2731 / 2734
页数：4
相关论文
共 14 条
[1]   Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma [J].
Doki, Y. ;
Ajani, J. A. ;
Kato, K. ;
Xu, J. ;
Wyrwicz, L. ;
Motoyama, S. ;
Ogata, T. ;
Kawakami, H. ;
Hsu, C. -H. ;
Adenis, A. ;
El Hajbi, F. ;
Di Bartolomeo, M. ;
Braghiroli, M. I. ;
Holtved, E. ;
Ostoich, S. A. ;
Kim, H. R. ;
Ueno, M. ;
Mansoor, W. ;
Yang, W. -C. ;
Liu, T. ;
Bridgewater, J. ;
Makino, T. ;
Xynos, I. ;
Liu, X. ;
Lei, M. ;
Kondo, K. ;
Patel, A. ;
Gricar, J. ;
Chau, I. ;
Kitagawa, Y. .
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (05) :449-462
[2]   SKYSCRAPER-08: A phase III, randomized, double-blind, placebo-controlled study of first-line (1L) tiragolumab (tira) plus atezolizumab (atezo) and chemotherapy (CT) in patients (pts) with esophageal squamous cell carcinoma (ESCC). [J].
Hsu, Chih-Hung ;
Lu, Zhihao ;
Gao, Shegan ;
Wang, Jun-Ye ;
Sun, Jong-Mu ;
Liu, Tianshu ;
Fan, Qingxia ;
Cai, Jun ;
Ge, Feijiao ;
Li, Sijing ;
Zhang, Li ;
Cha, Edward ;
Shen, Lin .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) :245-245
[3]   Emerging Multimodality Approaches to Treat Localized Esophageal Cancer [J].
Kelly, Ronan J. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (08) :1009-1014
[4]   Optimizing lymph node dissection can better for accurate assessment and management of lymph node recurrence in postoperative thoracic esophageal squamous cell carcinoma [J].
Li, Kexun ;
Zhao, Jie ;
Wei, Xueqiang ;
Chen, Xiaobo ;
Mao, Jie ;
Huang, Yunchao ;
Yang, Jiapeng .
INTERNATIONAL JOURNAL OF SURGERY, 2025, 111 (01) :1-4
[5]   Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial [J].
Lu, Zhihao ;
Wang, Junye ;
Shu, Yongqian ;
Liu, Lianke ;
Kong, Li ;
Yang, Lei ;
Wang, Buhai ;
Sun, Guogui ;
Ji, Yinghua ;
Cao, Guochun ;
Liu, Hu ;
Cui, Tongjian ;
Li, Na ;
Qiu, Wensheng ;
Li, Gaofeng ;
Hou, Xinfang ;
Luo, Hui ;
Xue, Liying ;
Zhang, Yanqiao ;
Yue, Wenbin ;
Liu, Zheng ;
Wang, Xiuwen ;
Gao, Shegan ;
Pan, Yueyin ;
Galais, Marie-Pierre ;
Zaanan, Aziz ;
Ma, Zhuo ;
Li, Haoyu ;
Wang, Yan ;
Shen, Lin .
BMJ-BRITISH MEDICAL JOURNAL, 2022, 377
[6]   Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study [J].
Meng, Xiangrui ;
Wang, Junsheng ;
Xia, Jin ;
Wu, Tao ;
Luo, Zhiquan ;
Hong, Yonggui ;
Lu, Ping ;
Guo, Yanzhen ;
Ji, Yinghua ;
Zhang, Min ;
Yang, Liuzhong ;
Cheng, Peng ;
Liang, Wenchang ;
Shan, Zhengzheng ;
Zhou, Yue ;
Wang, Mingyue ;
Lu, Taiying ;
Song, Min ;
Zong, Hong ;
Song, Lijie ;
Wang, Wenkang ;
Guan, Lulu ;
Li, Yanke ;
Xing, Jianxiang ;
Xing, Siyuan ;
Wu, Han ;
Chu, Jingwen ;
Luo, Xi ;
Lu, Yao ;
Xin, Dao ;
Li, Aijia ;
Jiang, Binghua ;
Li, Shenglei ;
Jiang, Guozhong ;
Fan, Qingxia ;
Zhao, Feng ;
Zheng, Rongrong ;
Zhu, Wenqing ;
Hou, Zhiguo ;
Jia, Yun ;
Wang, Feng .
EUROPEAN JOURNAL OF CANCER, 2024, 212
[7]   Multimodality treatment of esophageal cancer: A review of the current status and future directions [J].
Ng T. ;
Dipetrillo T. ;
Purviance J. ;
Safran H. .
Current Oncology Reports, 2006, 8 (3) :174-182
[8]   Oesophageal carcinoma [J].
Pennathur, Arjun ;
Gibson, Michael K. ;
Jobe, Blair A. ;
Luketich, James D. .
LANCET, 2013, 381 (9864) :400-412
[9]   Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial [J].
Qin, Jianjun ;
Xue, Liyan ;
Hao, Anlin ;
Guo, Xiaofeng ;
Jiang, Tao ;
Ni, Yunfeng ;
Liu, Shuoyan ;
Chen, Yujie ;
Jiang, Hongjing ;
Zhang, Chen ;
Kang, Mingqiang ;
Lin, Jihong ;
Li, Hecheng ;
Li, Chengqiang ;
Tian, Hui ;
Li, Lin ;
Fu, Junke ;
Zhang, Yong ;
Ma, Jianqun ;
Wang, Xiaoyuan ;
Fu, Maoyong ;
Yang, Hao ;
Yang, Zhaoyang ;
Han, Yongtao ;
Chen, Longqi ;
Tan, Lijie ;
Dai, Tianyang ;
Liao, Yongde ;
Zhang, Weiguo ;
Li, Bin ;
Chen, Qixun ;
Guo, Shiping ;
Qi, Yu ;
Wei, Li ;
Li, Zhigang ;
Tian, Ziqiang ;
Kang, Xiaozheng ;
Zhang, Ruixiang ;
Li, Yong ;
Wang, Zhen ;
Chen, Xiankai ;
Hou, Zhiguo ;
Zheng, Rongrong ;
Zhu, Wenqing ;
He, Jie ;
Li, Yin .
NATURE MEDICINE, 2024, 30 (09) :2549-2557
[10]   A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial [J].
Shang, Xiaobin ;
Xie, Yongjie ;
Yu, Jinpu ;
Zhang, Chen ;
Zhao, Gang ;
Liang, Fei ;
Liu, Liang ;
Zhang, Weihong ;
Li, Runmei ;
Yu, Wenwen ;
Yue, Jie ;
Chen, Chuangui ;
Duan, Xiaofeng ;
Ma, Zhao ;
Chen, Zuoyu ;
Xiong, Yanjuan ;
Yang, Fan ;
Xiao, Jianyu ;
Zhang, Rui ;
Liu, Pengpeng ;
Cheng, Yanan ;
Cao, Fuliang ;
Guo, Feng ;
Liu, Guoyan ;
Meng, Bin ;
Zhou, Dejun ;
Sun, Yan ;
Ren, Xiubao ;
Yu, Jun ;
Hao, Jihui ;
Jiang, Hongjing .
CANCER CELL, 2024, 42 (10) :1747-1763.e7
12